YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street H PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Good morning. Stocks are off to a mixed start as all eyes turn toward Jackson Hole, where Kevin Warsh is set to give his first keynote speech as chairman of the Federal Reserve. In the bond market, yields throughout the curve are up by rou…
(RTTNews) - Quoin Pharmaceuticals Ltd. (QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, reported second-quarter 2026 results and provided a corporate update highlighting progress across it…
(RTTNews) - Quoin Pharmaceuticals Ltd. (QNRX) on Thursday said the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), allowing the compa…
(RTTNews) - Today's top gainers include Pulsenmore, which has entered into a collaboration with Ouma Health, a provider of virtual maternity care solutions in the United States; IceCure Medical, whose ProSense technology was validated in a…
(RTTNews) - Quoin Pharmaceuticals, Ltd. (QNRX), a late clinical-stage pharmaceutical company, announced that it has received the orphan drug designation for QRX003 from Japan's Ministry of Health, Labour and Welfare, or MHLW, for the treat…
(RTTNews) - Quoin Pharmaceuticals Ltd. (QNRX), a late-stage clinical company, provided a clinical and regulatory update on its QRX009 topical rapamycin development programs. The firm noted that it plans to initiate investigator-led clinica…
Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications. Company to Initiate Investigator Led Clinical Study in Pachyonychia Congenita Study Will be Led By Professor Edel O’…
(RTTNews) - Quoin Pharmaceuticals Ltd. (QNRX), a late-stage clinical company, provided a clinical and regulatory update following its recent Type C meeting with the U.S. Food and Drug Administration for its lead product candidate, QRX003,…
– Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D – Sally Lawlor Appointed CFO to Support Commercialization and Financial Operations – Orphan Drug Designation Awarded by FDA to QRX003 f…
ASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans…
Quoin Pharmaceuticals (QNRX) shares soared 126% amid heavy trading intraday after the company said F PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
ASHBURN, Va., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has e…
ASHBURN, Va., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the release…
* Quoin Pharmaceuticals (NASDAQ:QNRX [https://seekingalpha.com/symbol/QNRX]) on Monday announced the appointment of Sally Lawlor as its new Chief Financial Officer as the company advances its lead product candidate, QRX003, through pivotal…
Quoin Pharmaceuticals, Inc. ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, t…
ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointme…
Key Points GAAP EPS of 6.28 was better than the estimated -6.82 for Q2 2025, GAAP EPS of 6.28 exceeded the estimate by $13.10 per share for Q2 2025. Research and development expenses more than tripled to $2.05 million in Q2 2025 compared t…
Quoin Pharmaceuticals Ltd-Adr (NASDAQ:QNRX [https://www.chartmill.com/stock/quote/QNRX/profile]) reported its second-quarter 2025 financial results, posting an earnings per share (EPS) of -$6.28, which was narrower than the analyst consens…
Investing.com -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) stock rose 2.4% following the company’s update on its development product portfolio, highlighting progress in its lead product for Netherton Syndrome and other rare skin disease tre…
Lead Product, QRX003, Being Tested in Two Active Registrational Clinical Studies for Netherton Syndrome Across the U.S., Europe, and the Middle East. QRX003 Peeling Skin Syndrome Clinical Program Continues Following Positive Initial Data T…
Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX), a micro-cap pharmaceutical company with a market capitalization of $5.22 million, announced Monday that Chief Financial Officer Gordon Dunn will be leaving the company following a mutual agreement…
ASHBURN, Va., June 26, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the release o…
Study CL-QRX003-002 will test whole-body application of QRX003 in conjunction with off-label systemic therapy in approximately 12-15 subjects.Study CL-QRX003-002 complements first whole-body pivotal study, CL-QRX003-003, being led by Dr. A…
Clear Improvement in Patient’s Skin Appearance Observed in Study after 12 weeks Compared to BaselineKey endpoints including Investigator’s Global Assessment (IGA), Modified Ichthyosis Area Severity (M-IASI) and Children’s Dermatology Life…
ASHBURN, Va., April 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic…
Episode Highlights a Truly Remarkable Patient Story Spanning 79 Years Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the company’s NETHERTON N…
Enable social media cookies to share Monday's session: gap up and gap down stocks By Mill Chart Last update: Apr 7, 2025 The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-…
Enable social media cookies to share Discover the top movers in Monday's pre-market session. By Mill Chart Last update: Apr 7, 2025 Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and l…
Continued Clear Visual Evidence of Almost Completely Healed Skin After 6 weeks TreatmentHigh Durability of Treatment Effect of QRX003 with Continuous Daily Dosing Patient Continues Not to Require Previously Necessary MedicationsWith Patien…
Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic DermatitisThird Quoin Patent Application for Netherton Syndrome If Granted Company Would have Patent Protection for QRX003 for…
Groundbreaking data from first whole body application of QRX003 underscores potential efficacyTransformational improvement in disease state after just 2 weeks of treatment Clear visual evidence of skin healing observedImprovement has elimi…
ASHBURN, Va., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the launch of…
Multi-pronged media campaign to raise awareness about the disease and its impact on patients, family members and caregivers.Interactive, stand-alone NETHERTON NOW website launched.Quoin’s QRX003 product is on track to obtain the first regu…
Company reported positive clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study Positive benefits were observed across a number of clinical endpoints including pruritus, Investigator skin…
ASHBURN, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company p…